Recall Z-1519-2018— Roche Diagnostics Corporation

Class II · Terminated

Class II FDA medical device recall by Roche Diagnostics Corporation, initiated 2018-01-02, terminated 2019-04-25. It names one FDA 510(k) clearance: K110726. Product: Roche Acetaminophen assay 03255379160-HAcetaminophen (P) 20767174160- cobas c Integra AAcetaminophen150 test. Reason: The previous version of method sheets for the Acetaminophen assay on the COBAS INTEGRA 400 plus/800/800 CTS analyzers and the MODULAR ANALYTICS P module are missing the following statement in the Limitations-interference section: "In very rare cases, gammopathy, in particular type IgM (Waldenstr¿m s macroglobulinemia), may cause unreliable results.".

Recalling firm
Roche Diagnostics Corporation
Classification
Class II
Status
Terminated
Initiated
2018-01-02
Terminated
2019-04-25
Firm location
Indianapolis, IN, United States

510(k) clearances named in this recall

1 on FDA's record

K-numbers as listed on FDA's Recall Enterprise System record for this event (openFDA device/recall k_numbers). The recall may also cover devices cleared under other submissions not named here.

Product description

Roche Acetaminophen assay 03255379160-HAcetaminophen (P) 20767174160- cobas c Integra AAcetaminophen150 test

Reason for recall

The previous version of method sheets for the Acetaminophen assay on the COBAS INTEGRA 400 plus/800/800 CTS analyzers and the MODULAR ANALYTICS P module are missing the following statement in the Limitations-interference section: "In very rare cases, gammopathy, in particular type IgM (Waldenstr¿m s macroglobulinemia), may cause unreliable results."

Data sourced from openFDA. This site is unofficial and independent of the FDA.